Temozolomide in aggressive pituitary adenomas and carcinomas

Clinics

Volumn 67, Issue SUPPLEMENT, 2012, Pages 119-123

  Ortiz, Leon D ^a   Syro, Luis V ^b   Scheithauer, Bernd W ^c   Rotondo, Fabio ^d   Uribe, Humberto ^e   Fadul, Camilo E ^f   Horvath, Eva ^d   Kovacs, Kalman ^d  

^a Section of Neuro oncology   (Colombia)

^b HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^c MAYO CLINIC   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e Clinica SOMA   (Colombia)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

MGMT; Pituitary adenoma; Pituitary carcinoma; Review; Temozolomide

Indexed keywords

ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; TEMOZOLOMIDE;

ADENOMA; CARCINOMA; HUMAN; HYPOPHYSIS TUMOR; REVIEW;

ADENOMA; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA; DACARBAZINE; HUMANS; PITUITARY NEOPLASMS;

EID: 84863965131     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(Sup01)20     Document Type: Review

References (55)

1. Buchfelder M. Management of aggressive pituitary adenomas: current treatment strategies. Pituitary. 2009;12(3):256-60, http://dx.doi.org/10.1007/s11102-008-0153-z.
2. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90(5):3089-99, http://dx.doi.org/10.1210/jc.2004-2231.
3. Colao A, Ochoa AS, Auriemma RS, Faggiano A, Pivonello R, Lombardi G. Pituitary carcinomas. Front Horm Res. 2010;38:94-108, http://dx.doi.org/10.1159/000318499.
4. Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WFJr., et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer. 1997;79(4):804-12, http://dx.doi.org/10.1002/(SICI)1097-0142(19970215)79: 4,804::AID-CNCR18.3.0.CO;2-3.
5. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7(6):518-20, http://dx.doi.org/10.1016/S1470-2045(06)70728-8.
6. Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg. 2006;105(4):621-6.
7. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, et al. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf). 2006;65(4):552-3, http://dx.doi.org/10.1111/j.1365-2265.2006.02653.x.
8. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol. 2007;38(1):185-9, http://dx.doi.org/10.1016/j.humpath.2006.07.014.
9. Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, et al. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary. 2007;10(1):81-6, http://dx.doi.org/10.1007/s11102-007-0014-1.
10. Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 2008;115(2):261-2, http://dx.doi.org/10.1007/s00401-007-0279-5.
11. Debono M, Bridgewater C, Ross R, Newell-Price J. Treating an aggressive prolactinoma in a patient with MEN 1: beneficial response to temozolomide. Society for Endocrinology BES; Endocrine Abstracts. 2008;15:188.
12. Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, et al. Treatment of Nelson's syndrome with temozolomide. Eur J Endocrinol. 2009;160(1):115-9.
13. 6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf). 2009;71(2):226-33, http://dx.doi.org/10.1111/j.1365-2265.2008.03487.x.
14. Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD. Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery. 2009;64(4):E773-4; discussion E4, http://dx.doi.org/10.1227/01.NEU.0000339115.12803.4E
15. 6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. Eur J Endocrinol. 2009;161(4):553-9, http://dx.doi.org/10.1530/EJE-09-0414.
16. Hagen C, Schroeder HD, Hansen S, Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol. 2009;161(4):631-7, http://dx.doi.org/10.1530/EJE-09-0389.
17. Byrne S, Karapetis C, Vrodos N. A novel use of temozolomide in a patient with malignant prolactinoma. J Clin Neurosci. 2009;16(12):1694-6, http://dx.doi.org/10.1016/j.jocn.2009.05.013.
18. Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL. Temozolomide (TemodarH) and capecitabine (XelodaH) treatment of an aggressive corticotroph pituitary tumor. Pituitary. 2011;14(4):418-24, http://dx.doi.org/10.1007/s11102-009-0211-1.
19. Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Horvath E, Rotondo F, et al. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones (Athens). 2009;8(4):303-6.
20. Morin E, Berthelet F, Weisnagel J, Bidlingmaier M, Serri O. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary. In press; http://dx.doi.org/10.1007/s11102-010-0232-9.
21. Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, et al. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes. 2010;118(10):760-3, http://dx.doi.org/10.1055/s-0030-1253419.
22. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95(10):4592-9, http://dx.doi.org/10.1210/jc.2010-0644.
23. 6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 2010;95(11):E280-90, http://dx.doi.org/10.1210/jc.2010-0441.
24. Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer. 2011;117(3):454-62, http://dx.doi.org/10.1002/cncr.25413.
25. Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, et al. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol. 2010;163(6):843-51, http://dx.doi.org/10.1530/EJE-10-0629.
26. Dillard TH, Gultekin SH, Delashaw JBJr., Yedinak CG, Neuwelt EA, Fleseriu M. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary. 2011;14(1):80-91, http://dx.doi.org/10.1007/s11102-010-0264-1.
27. Curtò L, Torre ML, Ferrau F, Pitini V, Altavilla G, Granata F, et al. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease: report of a case and literature review. Scientific World Journal. 2010;10:2132-8.
28. Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, et al. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma. Neurosurgery. 2011;68(6):E1761-7, http://dx.doi.org/10.1227/NEU.0b013e318217161a.
29. Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, et al. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy. Hormones (Athens). 2011;10(2):162-7.
30. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47(22):5846-52.
31. Neidle S, Thurston DE. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer. 2005;5(4):285-96, http://dx.doi.org/10.1038/nrc1587.
32. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2001;2(9):552-60, http://dx.doi.org/10.1016/S1470-2045(01)00489-2.
33. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96, http://dx.doi.org/10.1056/NEJMoa043330.
34. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009;64(4):647-55, http://dx.doi.org/10.1007/s00280-009-1050-5.
35. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24(3):401-6, http://dx.doi.org/10.1200/JCO.2005.03.6046.
36. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000;5(2):144-51, http://dx.doi.org/10.1634/theoncologist.5-2-144.
37. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist. 2007;12(9):1114-23, http://dx.doi.org/10.1634/theoncologist.12-9-1114.
38. Shacham-Shmueli E, Beny A, Geva R, Blachar A, Figer A, Aderka D. Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine? J Clin Oncol. 2011;29(10):e262-5, http://dx.doi.org/10.1200/JCO.2010.32.0242.
39. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009;27(23):3861-7, http://dx.doi.org/10.1200/JCO.2008.20.7944.
40. Mrugala MM, Chamberlain MC. Mechanisms of disease: temozolomide and glioblastoma: look to the future. Nat Clin Pract Oncol. 2008;5(8):476-86, http://dx.doi.org/10.1038/ncponc1155.
41. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006;12(2):328-31, http://dx.doi.org/10.1158/1078-0432.CCR-05-2543.
42. Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'Neill BP, et al. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol. 2008;16(1):59-65.
43. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol. 2002;20(9):2388-99, http://dx.doi.org/10.1200/JCO.2002.06.110.
44. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59(4):793-7.
45. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K. Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res. 2009;29(10):3759-68.
46. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350-4, http://dx.doi.org/10.1056/NEJM200011093431901.
47. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003, http://dx.doi.org/10.1056/NEJMoa043331.
48. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16(12):3851-7.
49. Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab. 1998;83(12):4233-8, http://dx.doi.org/10.1210/jc.83.12.4233.
50. Scheithauer BW, Horvath E, Kovacs K, Lloyd RV, Stefaneanu L, Buchfelder M, et al. Prolactin-producing pituitary adenoma and carcinoma with neuronal components: a metaplastic lesion. Pituitary. 1999;1(3-4):197-205, http://dx.doi.org/10.1023/A:1009913303109.
51. McCormack AI, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest. 2011;41(10):1133-48, http://dx.doi.org/10.1111/j.1365-2362.2011. 02520.x.
52. 6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol. 2006;24(21):3431-7, http://dx.doi.org/10.1200/JCO.2006.05.7265.
53. 6-Methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer. 2009;115(5):1070-80, http://dx.doi.org/10.1002/cncr.24053.
54. Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary. 2010;13(4):367-79, http://dx.doi.org/10.1007/s11102-010-0249-0.
55. Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Erickson D, et al. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neurooncol. 2011;104(3):647-57, http://dx.doi.org/10.1007/s11060-011-0532-6.